Gossamer Bio, Inc. (GOSS): Nasdaq/NYSE listing notice — Gossamer Bio receives Nasdaq notice for non-compliance with $1.00 minimum bid price; 180-day cure period.

Gossamer Bio, Inc.

Nasdaq notified Gossamer Bio on Oct 19, 2023 that its common stock had a closing bid price below $1.00 for 30 consecutive business days.
Company has until April 16, 2024 to regain compliance by maintaining at least $1.00 closing bid for 10 consecutive business days.
If not compliant by deadline, Gossamer may transfer to Nasdaq Capital Market for an additional 180-day cure period.
Company is evaluating options including a potential reverse stock split; no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Gossamer Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

hrough October 18, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until April 16, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.

View on SEC.gov

Browse all listing & compliance notices →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.